Cyclin D1 is a key cell cycle regulatory protein, the expression and subcel
lular localization of which is often altered in human tumor cells. A common
A/G single nucleotide polymorphism (A870G) in exon 4 of the cyclin D1 gene
, CCND1, is associated with the presence of 2 distinct mRNA transcripts for
this G1/S regulatory protein, and CCND1 genotype has been related to progn
osis in lung cancer and head and neck carcinoma. We have investigated both
the expression of cyclin D1 protein and the CCND1 A870G polymorphism in 100
colorectal cancer patients. Immunohistochemistry demonstrated cyclin D1 pr
otein expression in 55% of tumors, and while the absence of cyclin D1 prote
in was not associated with outcome (p = 0.81), high levels of protein expre
ssion (>50% of tumor cells expressing cyclin D1) correlated with significan
tly shortened overall survival (p = 0.01). Using polymerase chain reaction
restriction fragment length polymorphism analysis, we determined the freque
ncy of each genotype and found that CCND1 genotype was not related to overa
ll survival (p > 0.05). In addition, genotype was unrelated to the level of
expression and localization of cyclin D1 protein, as well as other key G1/
S checkpoint proteins (p21, p27, p53, retinoblastoma) and tumor proliferati
on markers (proliferating cell nuclear antigen). However, higher levels of
p27, and to a lesser extent p21, were associated with reduced cytoplasmic c
yclin D1 protein (p = 0.029 and p = 0.054, respectively). In conclusion, we
have demonstrated that high levels of cyclin D1 protein expression are rel
ated to outcome in colorectal cancer; however, the CCND1 A870G polymorphism
is unrelated to either cyclin D1 protein expression or patient survival. (
C) 2000 Wiley-Liss, Inc.